Immunotherapy of hepatocellular carcinoma

Firouzeh Korangy Hannover Medical School, Hannover, Germany: Medical Oncology Branch, National Cancer Institute, NIH, Bldg. 10 Rm 12N226, 900 Rockville Pike, Rockville, MD, USA; Twincore Center for Experimental and Clinical Research Medical School Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany; Hannover Medical School, Hannover, Germany: Medical Oncology Branch, National Cancer Institute, NIH, Bldg. 10 Rm 12N226, 900 Rockville Pike, Rockville, MD, USA; Twincore Center for Experimental and Clinical Research Medical School Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany

Bastian Höchst Hannover Medical School, Hannover, Germany: Medical Oncology Branch, National Cancer Institute, NIH, Bldg. 10 Rm 12N226, 900 Rockville Pike, Rockville, MD, USA; Twincore Center for Experimental and Clinical Research Medical School Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany; Hannover Medical School, Hannover, Germany: Medical Oncology Branch, National Cancer Institute, NIH, Bldg. 10 Rm 12N226, 900 Rockville Pike, Rockville, MD, USA; Twincore Center for Experimental and Clinical Research Medical School Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany

Michael P Manns Hannover Medical School, Hannover, Germany: Medical Oncology Branch, National Cancer Institute, NIH, Bldg. 10 Rm 12N226, 900 Rockville Pike, Rockville, MD, USA; Hannover Medical School, Hannover, Germany: Medical Oncology Branch, National Cancer Institute, NIH, Bldg. 10 Rm 12N226, 900 Rockville Pike, Rockville, MD, USA

Tim F Greten Hannover Medical School, Hannover, Germany: Medical Oncology Branch, National Cancer Institute, NIH, Bldg. 10 Rm 12N226, 900 Rockville Pike, Rockville, MD, USA; Twincore Center for Experimental and Clinical Research Medical School Hannover, Carl Neuberg Str. 1, 30625 Hannover, Germany;[email protected]

Abstract

Hepatocellular carcinoma (HCC) represents the third most common cause of cancer-related death worldwide and efficient treatment options are urgently needed. Based on its pathogenesis, in addition to a number of correlative studies, immunotherapy represents a potential therapeutic option for patients with HCC. However, tumors have also evolved numerous immune escape mechanisms, including the generation of cells with immune suppressor functions, such as Tregs and myeloid-derived suppressor cells. It has been shown that these suppressor cells mask tumor-specific immune responses in patients with HCC. Different immunotherapeutic approaches including peptide- and dendritic cell-based therapies have demonstrated promising results in patients with HCC. However, we propose that any of these immunotherapeutic approaches needs to be combined with a therapy specifically targeting suppressor cells in HCC.

Keywords::

Financial & competing interests disclosure

This work was supported by grants from the Deutsche Forschungsgemeinschaft (DFG; KFO119) and by the Initiative and Networking Fund of the Helmholtz Association within the Helmholtz Alliance on Immunotherapy of Cancer. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Immunotherapy of hepatocellular carcinoma

Information for

Open access

Opportunities

Help and information

Immunotherapy of hepatocellular carcinoma

Abstract

Financial & competing interests disclosure

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature